Company intelligence / Profile preview
Emalex Biosciences
Chicago, Illinois, United Statesemalexbiosciences.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Emalex’s lead candidate, ecopipam—a novel dopamine D1 receptor antagonist—met primary and secondary endpoints in a Phase 3 trial for Tourette syndrome. The company plans to submit an NDA following positive results showing statistically significant reduction in relapse rates compared to placebo among pediatric subjects.
- Therapeutic areas
- Neurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Emalex Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Emalex Biosciences.